CN109069504B - 氨基噻唑化合物及其用途 - Google Patents

氨基噻唑化合物及其用途 Download PDF

Info

Publication number
CN109069504B
CN109069504B CN201780010118.4A CN201780010118A CN109069504B CN 109069504 B CN109069504 B CN 109069504B CN 201780010118 A CN201780010118 A CN 201780010118A CN 109069504 B CN109069504 B CN 109069504B
Authority
CN
China
Prior art keywords
cancer
compound
compounds
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780010118.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069504A (zh
Inventor
姜韦汤
许楚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
Taiwan Institute Of Health
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Institute Of Health, National Health Research Institutes filed Critical Taiwan Institute Of Health
Publication of CN109069504A publication Critical patent/CN109069504A/zh
Application granted granted Critical
Publication of CN109069504B publication Critical patent/CN109069504B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201780010118.4A 2016-02-05 2017-01-31 氨基噻唑化合物及其用途 Active CN109069504B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291667P 2016-02-05 2016-02-05
US62/291,667 2016-02-05
PCT/US2017/015765 WO2017136315A1 (en) 2016-02-05 2017-01-31 Aminothiazole compounds and use thereof

Publications (2)

Publication Number Publication Date
CN109069504A CN109069504A (zh) 2018-12-21
CN109069504B true CN109069504B (zh) 2022-06-28

Family

ID=59496120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780010118.4A Active CN109069504B (zh) 2016-02-05 2017-01-31 氨基噻唑化合物及其用途

Country Status (8)

Country Link
US (1) US10047078B2 (enExample)
EP (1) EP3411035B1 (enExample)
JP (1) JP6883049B2 (enExample)
KR (1) KR102449712B1 (enExample)
CN (1) CN109069504B (enExample)
ES (1) ES2909612T3 (enExample)
TW (1) TWI620748B (enExample)
WO (1) WO2017136315A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
CA3246244A1 (en) 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. CANCER COMPOSITIONS AND TREATMENT METHODS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225880A1 (en) * 2011-03-04 2012-09-06 National Health Research Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
US20130150364A1 (en) * 2010-08-10 2013-06-13 Astellas Pharma Inc. Heterocyclic compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366932C (en) * 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ES2257461T3 (es) * 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
EP1558609A4 (en) * 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS
KR100919905B1 (ko) * 2005-01-26 2009-10-06 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
AU2008355098B2 (en) 2008-04-21 2012-11-15 Gpcr Therapeutics, Inc Heterocyclic compounds
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150364A1 (en) * 2010-08-10 2013-06-13 Astellas Pharma Inc. Heterocyclic compound
US20120225880A1 (en) * 2011-03-04 2012-09-06 National Health Research Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors

Also Published As

Publication number Publication date
TW201728583A (zh) 2017-08-16
US20170226100A1 (en) 2017-08-10
ES2909612T3 (es) 2022-05-09
KR20180132618A (ko) 2018-12-12
EP3411035B1 (en) 2022-03-02
EP3411035A1 (en) 2018-12-12
KR102449712B1 (ko) 2022-09-30
TWI620748B (zh) 2018-04-11
JP2019511564A (ja) 2019-04-25
US10047078B2 (en) 2018-08-14
WO2017136315A1 (en) 2017-08-10
EP3411035A4 (en) 2019-08-14
HK1258689A1 (zh) 2019-11-15
JP6883049B2 (ja) 2021-06-02
CN109069504A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
EP3411035B1 (en) Aminothiazole compounds and use thereof
KR102618773B1 (ko) 디아릴 거대환형 화합물을 수반하는 병용 요법
JP7058345B2 (ja) Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
JP6637884B2 (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
TW202007396A (zh) Bcl-2抑制劑或Bcl-2/Bcl-xL抑制劑與BTK抑制劑的組合產品及其在預防和/或治療疾病中的用途
TWI726362B (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用
SG178351A1 (en) Compounds and compositions as protein kinase inhibitors
CN114867622A (zh) 涉及二芳基巨环化合物的组合疗法
CN114901286B (zh) 涉及二芳基巨环化合物的组合疗法
AU2022201717B2 (en) Treatment of cancer
KR20240004548A (ko) 암 치료를 위한 pcna 억제제 및 egfr 억제제
JP2020523348A (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
PT2182948E (pt) Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr
WO2015112705A2 (en) Therapeutic combinations for treating cancer
CN112237579B (zh) 药物组合及其用途
HK1258689B (en) Aminothiazole compounds and use thereof
JP7200453B2 (ja) Ａｘｌ阻害剤として使用するためのピリドピリミジノン誘導体
JP2014034531A (ja) Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ
RU2784853C2 (ru) Комбинационная терапия с применением диарильных макроциклических соединений
HK40035225A (en) Pharmaceutical combination and use thereof
EP4441052A1 (en) Compounds
HK40017909A (en) Aminothiazole compounds as protein kinase inhibitors
ZA200306404B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190325

Address after: Miaoli County, Taiwan, China

Applicant after: National Health Research Institutes

Address before: Miaoli County, Taiwan, China

Applicant before: National Health Research Institutes

Applicant before: Shi Quan

TA01 Transfer of patent application right
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258689

Country of ref document: HK

CB02 Change of applicant information

Address after: Miaoli County, Taiwan, China

Applicant after: Taiwan Institute of health

Address before: Miaoli County, Taiwan, China

Applicant before: NATIONAL HEALTH RESEARCH INSTITUTES

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information

Inventor after: Jiang Weitang

Inventor after: Xu Shi

Inventor before: Jiang Weitang

Inventor before: Xu Chu

CB03 Change of inventor or designer information